DCPS Protein (Decapping Scavenger)

DCPS Protein (Decapping Scavenger)

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DCPS Protein (Decapping Scavenger)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DCPS</td>
</tr>
<tr>
<td class="label">Official Name</td>
<td>Decapping Enzyme, Scavenger</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>DCP2, DXO, D9Ertd320e (mouse)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10260</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9GZX0</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137693</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>340 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~38 kDa</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>DCPS Relevance</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>High</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>High</td>
</tr>
<tr>
<td class="label">AD</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Ye et al.</td>
<td>2025</td>
</tr>
<tr>
<td class="label">GWAS</td>
<td>2024</td>
</tr>
<tr>
<td class="label">Mugrida et al.</td>
<td>2015</td>
</tr>
<tr>
<td class="la

DCPS Protein (Decapping Scavenger)

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DCPS Protein (Decapping Scavenger)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DCPS</td>
</tr>
<tr>
<td class="label">Official Name</td>
<td>Decapping Enzyme, Scavenger</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>DCP2, DXO, D9Ertd320e (mouse)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10260</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9GZX0</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137693</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>340 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~38 kDa</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>DCPS Relevance</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>High</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>High</td>
</tr>
<tr>
<td class="label">AD</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Ye et al.</td>
<td>2025</td>
</tr>
<tr>
<td class="label">GWAS</td>
<td>2024</td>
</tr>
<tr>
<td class="label">Mugrida et al.</td>
<td>2015</td>
</tr>
<tr>
<td class="label">Wang et al.</td>
<td>2023</td>
</tr>
<tr>
<td class="label">Chen et al.</td>
<td>2021</td>
</tr>
<tr>
<td class="label">Song et al.</td>
<td>2023</td>
</tr>
<tr>
<td class="label">Reid et al.</td>
<td>2024</td>
</tr>
<tr>
<td class="label">De et al.</td>
<td>2024</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

DCPS (Decapping Scavenger Protein, also known as DCP2 or DXO decapping enzyme) is a specialized mRNA decapping enzyme that plays a critical role in eukaryotic mRNA turnover and decay pathways[@ye2025]. Originally characterized for its role in histone mRNA decapping and the quality control of aberrant mRNAs, DCPS has emerged as a significant player in neurodegenerative diseases through its regulation of [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology and RNA metabolism[@ye2025; @genomewide].

DCPS belongs to the HitDAP (His-acid phosphatase-DedA) hydrolase family and functions as a key component of the cytoplasmic mRNA decay machinery. The protein catalyzes the removal of the 5' cap structure (m7GpppN) from messenger RNA, converting the transcript into a substrate for 5'-to-3' exonucleolytic decay. This decapping step is a critical rate-limiting transition in the mRNA degradation pathway, and DCPS ensures proper processing of both normal and defective mRNAs[@mugrida2015].

In neurons, where RNA metabolism is particularly complex due to the high spatial specificity of local translation in axons and dendrites, DCPS plays an essential role in maintaining RNA homeostasis. Dysregulation of DCPS has been implicated in [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD), and [Alzheimer's disease](/diseases/alzheimers-disease) (AD), making it an important therapeutic target[@ye2025; @genomewide; @wang2023].

Gene and Protein Structure

Gene Information

Protein Domain Architecture

DCPS is a multidomain protein with several key structural features[@mugrida2015; @lester2016]:

The crystal structure of DCPS reveals a bipartite architecture with the catalytic domain forming a deep binding pocket for the m7G cap. The dimerization of DCPS creates an interface that enhances cap recognition and catalytic efficiency. Importantly, DCPS lacks the Nudix hydrolase motif found in some other decapping enzymes, placing it in a distinct enzyme family[@mugrida2015].

Normal Physiological Function

mRNA Decapping and Turnover

DCPS catalyzes the hydrolysis of the 5' m7G cap structure of messenger RNA, a reaction that is the first step in 5'-to-3' mRNA decay[@mugrida2015; @chaudhury2018]:

Cap structure recognition: The m7G cap is bound by DCPS with high affinity, positioning the scissile bond for nucleophilic attack Decapping chemistry: The catalytic mechanism involves a metal-dependent hydrolysis reaction, releasing m7GDP and leaving a 5'-phosphate on the decapped RNA Product processing: The decapped RNA is then rapidly degraded by the 5'-to-3' exonuclease XRN1

The decapping reaction is tightly regulated and serves multiple biological purposes:

• mRNA turnover: Decapping is a rate-limiting step in normal mRNA decay, allowing rapid changes in gene expression
• Quality control: DCPS preferentially decaps aberrant mRNAs with premature termination codons, targeting them for nonsense-mediated decay (NMD)[@takahama2021]
• Histone mRNA metabolism: DCPS plays a specialized role in decapping replication-dependent histone mRNAs during cell cycle progression[@bhide2016]
• Translational regulation: The coupling of decapping with translation repression ensures that mRNAs are rapidly silenced when protein synthesis is not needed[@ng2019]

Role in RNA Granule Dynamics

DCPS localizes to and regulates the dynamics of cytoplasmic RNA granules, particularly [processing bodies (P-bodies)](/entities/p-bodies) and stress granules[@wang2023; @chang2023]:

Processing bodies (P-bodies): P-bodies are cytoplasmic foci enriched in components of the mRNA decay machinery, including DCPS, XRN1, DCP1A, and GW182. P-bodies function as sites of mRNA storage, decay, and quality control. DCPS localization to P-bodies is dynamic, increasing under conditions of active mRNA decay and stress.

Stress granules: Under cellular stress (oxidative stress, heat shock, viral infection), translation initiation is inhibited and mRNAs accumulate in stress granules. DCPS is recruited to stress granules where it may regulate the fate of stored mRNAs. The interplay between stress granules and P-bodies is critical for deciding whether an mRNA will be re-initiated, stored, or degraded[@chang2023; @li2019].

Ribonucleoprotein granules in neurons: In neurons, specialized RNA granules transport mRNAs along axons and dendrites for local translation. These granules contain DCPS and other decapping machinery, allowing spatially regulated mRNA decay at synaptic compartments. This local control of mRNA stability is critical for synaptic plasticity, learning, and memory formation[@wu2024; @zhang2022].

Interactions with RNA-Binding Proteins

DCPS physically and functionally interacts with several RNA-binding proteins relevant to neuronal function[@song2023; @gao2024]:

• [TDP-43](/mechanisms/tdp-43-proteinopathy): Direct functional interaction, with DCPS modulating TDP-43-mediated neurodegeneration through P-body regulation[@ye2025]
• FUS: Fused in sarcoma protein (ALS/FTD gene) interacts with decapping machinery components[@song2023]
• SMN complex: The spinal muscular atrophy protein complex, involved in snRNP biogenesis and RNA processing
• hnRNPs: Heterogeneous nuclear ribonucleoproteins involved in mRNA splicing, transport, and stability
• Cap-binding proteins: CBP80 and CBP20 of the nuclear cap-binding complex cooperate with DCPS in mRNA decay
• EDC4/Ge-1: A core scaffolding component of the decapping complex that recruits DCPS

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive neurodegenerative disease affecting motor [neurons](/entities/motor-neurons) in the brain and spinal cord. The majority of ALS cases (sporadic and familial) feature [TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathy — the abnormal aggregation and cytoplasmic mislocalization of TDP-43. DCPS has emerged as a critical modifier of TDP-43-mediated neurotoxicity[@ye2025; @genomewide].

TDP-43 Regulation

A 2025 study by Ye et al. used genome-wide CRISPRi screening in human neurons to identify DCPS as a novel genetic modifier of TDP-43 loss-of-function neurotoxicity[@ye2025]:

Mechanistic insights: The study demonstrated that TDP-43 loss-of-function leads to aberrant mRNA degradation by disrupting the properties and function of P-bodies. DCPS modulates the dynamic equilibrium and assembly of these ribonucleoprotein (RNP) granules.

Therapeutic potential: Critically, reducing DCPS (via CRISPRi or small interfering RNA) restores P-body integrity and RNA turnover, ultimately improving neuronal survival. This suggests that DCPS is a potential therapeutic target for TDP-43 proteinopathy-related neurodegenerative diseases[@ye2025].

P-body disruption in ALS: In ALS, TDP-43 pathology disrupts P-body assembly and function. P-bodies are sites where non-translatable mRNAs accumulate for decay or storage. When TDP-43 function is compromised, P-bodies become dysregulated, leading to the accumulation of aberrant mRNAs and the formation of toxic aggregates. DCPS sits at the intersection of this pathway — its activity needs to be precisely balanced to maintain RNA homeostasis[@wang2023; @liu2022].

Genetic Associations

Genome-wide association studies have identified DCPS variants in ALS risk cohorts, suggesting that common genetic variation in DCPS may modify disease susceptibility[@genomewide]. Additionally, transcriptomic analyses of ALS motor cortex reveal altered DCPS expression, further supporting its involvement in disease pathogenesis[@de2024].

Pathogenic Mechanisms

Frontotemporal Dementia (FTD)

FTD is a spectrum of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. Like ALS, FTD is frequently associated with TDP-43 proteinopathy, and the two conditions overlap clinically, genetically, and pathologically (ALS-FTD spectrum).

Shared mechanisms: The TDP-43 proteinopathy seen in ALS overlaps significantly with FTD, and DCPS dysregulation contributes to both conditions through similar RNA metabolic mechanisms[@ye2025; @chen2021].

RNA dysregulation: Common mechanisms of RNA processing defects underlie both ALS and FTD, with DCPS positioned as a central modulator of this pathway.

Therapeutic implications: Given the shared TDP-43 pathology, DCPS modulators may benefit both ALS and FTD patients, offering a potential treatment strategy for the ALS-FTD spectrum[@reid2024].

Alzheimer's Disease

While less directly studied, DCPS may contribute to AD through several mechanisms[@de2024; @gao2024]:

RNA metabolism defects: Transcriptomic studies of AD brains reveal widespread RNA processing dysregulation, a process in which DCPS may play a role.

Stress response alterations: AD is characterized by cellular stress (oxidative stress, [neuroinflammation](/entities/neuroinflammation)), which alters stress granule dynamics. DCPS participates in stress granule biology and may be dysregulated in AD.

Protein homeostasis connections: DCPS links to [autophagy](/entities/autophagy) and proteostasis pathways through P-body function and RNA granule regulation.

TDP-43 pathology: A subset of AD cases also show TDP-43 pathology (limbic-predominant age-related TDP-43 encephalopathy, LATE), suggesting DCPS may be relevant in these cases[@chen2021].

Comparison Across Neurodegenerative Diseases

Molecular Interactions and Pathways

Protein Partners

DCPS interacts with several proteins critical to neurodegeneration[@song2023; @gao2024; @wu2024]:

• TDP-43 (TARDBP): Direct functional and physical interaction; DCPS modulates TDP-43-mediated neurodegeneration through P-body regulation[@ye2025]
• FUS: ALS/FTD gene encoding an RNA-binding protein; functionally interacts with decapping machinery[@song2023]
• SMN complex: Spinal muscular atrophy protein complex involved in snRNP biogenesis
• hnRNPs: Heterogeneous nuclear ribonucleoproteins (hnRNP A1, hnRNP A2/B1, hnRNP K)
• Cap-binding complex: CBP80/CBP20 of the nuclear cap-binding complex
• Decapping complex: DCP1A, DCP2, EDC4/Ge-1 scaffolding proteins
• Exonuclease: XRN1 (5'-to-3' exoribonuclease 1)
• GW182 (TNRC6A/B/C): Key P-body component involved in miRNA-mediated silencing

Signaling Pathways

• p53 pathway: DCPS deficiency activates p53-dependent [apoptosis](/entities/apoptosis)[@ng2019]
• Integrated stress response (ISR): DCPS dysregulation activates eIF2α phosphorylation and translational control
• Cell death pathways: Connections to both apoptotic and necroptotic cell death machinery
• mTOR pathway: Links to translational regulation through mRNA decapping

Therapeutic Implications

DCPS represents a promising therapeutic target for ALS and related neurodegenerative diseases[@ye2025; @reid2024]:

Enhancement Strategies

• Small molecule activators: Compounds that boost DCPS activity to restore P-body function and RNA turnover in TDP-43 pathology
• Gene therapy: AAV-mediated delivery of DCPS or DCPS-modulating constructs to the CNS
• ASO approaches: Antisense oligonucleotides targeting DCPS expression (knockdown in gain-of-function scenarios)

Indirect Targeting

• P-body stabilization: Compounds that preserve P-body function and integrity without directly targeting DCPS
• TDP-43 clearance: Indirect approaches through RNA metabolism enhancement
• Combination therapy: Simultaneous targeting of DCPS and other ALS/FTD therapeutic targets

Challenges

• Delivery: Getting therapeutic agents across the [blood-brain barrier](/entities/blood-brain-barrier) is a significant challenge
• Dosing: The therapeutic window for DCPS modulation is narrow — too much or too little can be harmful
• Selectivity: Achieving specificity for DCPS over related decapping enzymes
• Biomarkers: Lack of established biomarkers for DCPS pathway activity

Research Evidence

Key Studies

Model Systems

• Yeast models: Homologous decapping enzymes (Dcs1/Dcs2) studied in S. cerevisiae
• Human neurons: CRISPRi screens in iPSC-derived human motor neurons[@ye2025]
• Cell culture: Neuronal (NSC-34, SH-SY5Y) and glial cell models
• Animal models: Drosophila and mouse models of DCPS manipulation

Clinical Development Status

DCPS-targeted therapies are in early preclinical stages. The 2025 CRISPRi screen findings provide a strong rationale for drug discovery efforts targeting the DCPS-TDP-43 axis in ALS/FTD[@ye2025].

Mermaid Diagram: DCPS in TDP-43 Pathology

See Also

• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [ALS Gene Overview](/diseases/amyotrophic-lateral-sclerosis)
• [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
• [P-bodies and Stress Granules](/entities/p-bodies)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [mRNA Decay Pathways](/mechanisms/mrna-decay)
• [CRISPR Screening in Neurodegeneration](/experiments/crispr-screens-neurodegeneration)

External Links

• [UniProt: Q9GZX0](https://www.uniprot.org/uniprot/Q9GZX0)
• [NCBI Gene: DCPS](https://www.ncbi.nlm.nih.gov/gene/10260)
• [PubMed: DCPS neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=DCPS+ALS+TDP-43+neurodegeneration)
• [PDB: DCPS structure](https://www.rcsb.org/structure/5K2Q)